Epstein Secrets

lable USA Cleantech Fund #1 $35M ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DACART CAPITAL LLC EFTA_R1_01138806 EFTA02295532 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 M&A's, 1 IPO •

P, OM* • Growth factors, ctt(Npese Lumen Intim° [D.L-S P,FIT CAPITAL LLC EFTA_R1_01138815 EFTA02295541 Mechanism of Neointimal Thickening Medial SMC proliferation Lumen .Er-iclothelial cells Growth factors, ctfdlitits O° OO DACART CAPITAL Lac Intim° Adventitin EFTA_R1_01138816 EFTA02295542

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506111 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO • >$50

IMIP Lumen Intima Adventitia Fibroblasts, fat cells, interstitial matrix DACART CAPITAL LLC7 EFTA00506120 Mechanism of Neointimal Thickening Medial SMC proliferation () 0 0 0 0 0 0 0 Endothelial cells Growth factors, cit6b%-- oc) 00 Lumen Intima Fibroblasts, fat cells, interstitial IMP

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506160 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO •

110 411•1. 411Mir Fibroblasts, fat cells, interstitial matrix Adventitia DACART CAPITAL LLC7 EFTA00506173 Mechanism of Neointimal Thickening Medial SMC proliferation Adventitia Fibroblasts, fat cells, intersti '- ' DACART CAP' JAL LLC: EFTA00506174 SMC migration and neointimal lesion developmen